Investor Relations Agency, Access IR/PR, Adds Andrew Wiseman Ph.D. As Senior Consultant

Share Article

Access IR/PR, a senior level investor and public relations firm based in San Diego, announced today the addition of Andrew Wiseman, Ph.D., as Senior Consultant. Previously, Dr. Wiseman was a founder and executive with La Jolla Pharmaceutical Company.

Access IR/PR, a senior level investor and public relations firm based in San Diego, announced today the addition of Andrew Wiseman, Ph.D., as Senior Consultant. Previously, Dr. Wiseman was a founder and executive with responsibility for investor relations, business development, medical marketing and patient advocacy at La Jolla Pharmaceutical Company.

"The addition of Dr. Wiseman to our team of senior professionals further strengthens our organization and further positions us to provide high-value investor and public relations services to biopharmaceutical and other clients in the U.S. and abroad," said Scott Rieger, president of Access IR/PR. "Dr Wiseman is regarded by Wall Street as one of the more experienced scientific investor relations professionals in biotechnology and we welcome his expertise and many existing relationships within the investment community."

Dr. Wiseman brings more than 25 years of experience in the biotechnology industry, primarily in investor relations and medical communications. He has 15 years of experience managing the investor relations program inside a public company, and played an important role in bringing the company from a start up, through the IPO process, into the public company arena.

Dr. Wiseman was a founder and head of investor relations at La Jolla Pharmaceutical Company where he also was responsible for key opinion leader and patient advocacy development in support of the Company's efforts to bring the first drug to patients with systemic lupus erythematosus. He also led the Company's business development team for 10 years. He was a key player in the Company's successful fundraising of approximately $350 million from both private and public investors in support of its product development activities. Prior to founding La Jolla Pharmaceutical, he worked in business development and product development at Quidel, an immunodiagnostics company.

Before joining the biotechnology industry, Dr. Wiseman was an Assistant Professor in the Department of Cell biology at the Research Institute of Scripps Clinic. He has a Ph.D. in Genetics, Cell and Molecular Biology from Duke University, Durham, North Carolina and was a Helen Hay Whitney Post-Doctoral Fellow at the California Institute of Technology in Pasadena, California.

About Access IR/PR
Access IR/PR's services include development, documentation and implementation of strategic investor relations and corporate communications programs, including execution of targeted investor, media, key opinion leader and industry outreach activities; development and execution of appropriate internal systems, policies and procedures; and training and counsel on current communications practices, trends and issues.

The firm's clients also benefit from highly valued, affiliate relationships with leading complementary graphic designers, web and social media developers and product marketing service providers. Public and private company consulting services support pre- or post-IPO and transaction oriented exit strategies, including access to and communications with appropriate investors and strategic partners in the biotechnology and pharmaceutical industry, counsel on corporate message and brand development, drafting of key positioning messages and related communications tools and materials including printed, digital and web-based media. For more information on ACCESS IR/PR, see http://www.accessirpr.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Scott Rieger

Andrew Wiseman Ph.D.
Visit website